Single chain Fragments of variable regions in the treatment of Familial ALS
可变区单链片段治疗家族性肌萎缩侧索硬化症
基本信息
- 批准号:8049184
- 负责人:
- 金额:$ 19.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdenovirusesAmyotrophic Lateral SclerosisAntibodiesBindingBiochemicalBody Weight decreasedCause of DeathCell Culture TechniquesCell DeathCell LineCell SurvivalCellsCessation of lifeComplementCuprozinc Superoxide DismutaseDataDevelopmentDiseaseDisease ProgressionEnzymesFamilial Amyotrophic Lateral SclerosisFutureHindlimbHumanImmunizationImmunoglobulin Variable RegionImpairmentInheritance PatternsInheritedIntraventricular InfusionInvestigationKnowledgeMonoclonal AntibodiesMotor NeuronsMutateMutationNeurodegenerative DisordersNeuronsNorth AmericaOnset of illnessPathogenesisPatientsProteinsRecombinant adeno-associated virus (rAAV)RecombinantsReflex actionReportingRoleSatellite VirusesSuggestionSuperoxide DismutaseTestingTherapeuticToxic effectTransfectionTransgenic MiceTreatment EfficacyUnited States National Institutes of HealthViruseffective therapygain of functioninterestkillingsloss of functionmouse modelmutantosmotic minipumpprotein protein interactionpublic health relevancevector
项目摘要
DESCRIPTION (provided by applicant): Approximately 10% of cases of amyotrophic lateral sclerosis (ALS) are familial (FALS), and 20% of these cases are caused by mutations in an enzyme called superoxide dismutase type 1 (SOD1). Several lines of evidence have made it clear that the reason for motor neuron death in FALS is not due to a deficiency in enzymatic activity by the mutated SOD1 protein, but due to toxicity of the mutant (MT) enzyme. One attractive hypothesis is that the mutations in the SOD1 protein cause it to misfold, and the misfolding leads to aggregation of SOD1 within the cell and an associated interference with normal protein-protein interactions important for cell survival. Relevant to this proposal is the recent demonstration that monoclonal antibodies that are MTSOD1-specific can be therapeutically effective in a MTSOD1 transgenic mouse model of FALS. It may be that single chain fragments of variable region (scFvs) of antibodies directed against MTSOD1 can complement anti-MTSOD1 monoclonal antibodies since scFvs provide the opportunity for expression intracellularly (as intrabodies). We have isolated a number of scFvs of antibodies directed against SOD1, including an scFv that is directed against A4V MTSOD1 - the most common mutation of SOD1 seen in North America, and one that usually causes death in less than a year. We now plan to: prepare additional scFvs against wild type and MTSOD1; test whether scFvs delivered by means of transfection or virus vector delivery decrease aggregate formation and/or toxicity of MTSOD1 expression in a MN cell line and primary MNs; test whether scFvs delivered by means of a replication-deficient recombinant adeno-associated virus (AAV) into FALS transgenic mice decrease MTSOD1 aggregation, delay the onset or slow the progression of disease These studies may clarify the reasons for cell death as well as identify possible therapeutic approaches for FALS patients with SOD1 mutations. The knowledge of the mechanisms responsible for motor neuron death in FALS and its treatment may guide us in our understanding of non-inherited ALS - especially since recent information suggests that biochemical changes in SOD1 may contribute to disease in non-inherited ALS.
PUBLIC HEALTH RELEVANCE: Amyotrophic lateral sclerosis (ALS) is a desperate disease in which there is no cure or effective treatment. This proposal involves raising antibodies directed against a protein that is mutated in some cases of familial ALS and has been implicated in the development of sporadic ALS. The antibodies that we raise may help understand the cause of ALS and potentially provide a direction for treatment of inherited ALS as well as sporadic ALS.
描述(由申请人提供):大约10%的肌萎缩侧索硬化症(ALS)病例是家族性的(FALS),其中20%的病例是由称为超氧化物歧化酶1型(SOD 1)的酶突变引起的。一些证据表明,在FALS中运动神经元死亡的原因不是由于突变的SOD 1蛋白酶活性的缺乏,而是由于突变的(MT)酶的毒性。一个有吸引力的假设是,SOD 1蛋白中的突变导致其错误折叠,错误折叠导致SOD 1在细胞内聚集,并干扰对细胞存活重要的正常蛋白质-蛋白质相互作用。与该提议相关的是最近的证明,即MTSOD 1特异性的单克隆抗体在FALS的MTSOD 1转基因小鼠模型中可以是治疗有效的。可能的是,针对MTSOD 1的抗体的可变区的单链片段(scFv)可以补充抗MTSOD 1单克隆抗体,因为scFv提供了细胞内表达的机会(作为胞内抗体)。我们已经分离出了许多针对SOD 1的抗体的scFv,包括针对A4 V MTSOD 1的scFv-北美最常见的SOD 1突变,并且通常在不到一年的时间内导致死亡。我们现在计划:测试通过转染或病毒载体递送的scFv是否降低MN细胞系和原代MN中MTSOD 1表达的聚集体形成和/或毒性;测试通过复制缺陷型重组腺相关病毒(AAV)递送到FALS转基因小鼠中的scFv是否减少MTSOD 1聚集,这些研究可能会阐明细胞死亡的原因,并为SOD 1突变的FALS患者确定可能的治疗方法。了解导致FALS运动神经元死亡的机制及其治疗方法可能会指导我们理解非遗传性ALS -特别是最近的信息表明,SOD 1的生化变化可能导致非遗传性ALS疾病。
公共卫生关系: 肌萎缩性侧索硬化症(ALS)是一种绝望的疾病,其中没有治愈或有效的治疗。该提议涉及针对在某些家族性ALS病例中突变的蛋白质产生抗体,并且该蛋白质与散发性ALS的发展有关。我们提出的抗体可能有助于了解ALS的病因,并可能为治疗遗传性ALS以及散发性ALS提供方向。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1.
- DOI:10.1016/j.nbd.2013.04.007
- 发表时间:2013-08
- 期刊:
- 影响因子:6.1
- 作者:Ghadge GD;Pavlovic JD;Koduvayur SP;Kay BK;Roos RP
- 通讯作者:Roos RP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RAYMOND Philip ROOS其他文献
RAYMOND Philip ROOS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RAYMOND Philip ROOS', 18)}}的其他基金
Pathogenesis of Theiler's virus-induced demyelinating disease
泰勒病毒引起的脱髓鞘病的发病机制
- 批准号:
9093302 - 财政年份:2016
- 资助金额:
$ 19.56万 - 项目类别:
Guanabenz in the treatment of mutant SOD1 ALS mice
胍那苯治疗突变型 SOD1 ALS 小鼠
- 批准号:
8442820 - 财政年份:2012
- 资助金额:
$ 19.56万 - 项目类别:
Guanabenz in the treatment of mutant SOD1 ALS mice
胍那苯治疗突变型 SOD1 ALS 小鼠
- 批准号:
8280775 - 财政年份:2012
- 资助金额:
$ 19.56万 - 项目类别:
Single chain Fragments of variable regions in the treatment of Familial ALS
可变区单链片段治疗家族性肌萎缩侧索硬化症
- 批准号:
7904720 - 财政年份:2010
- 资助金额:
$ 19.56万 - 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
- 批准号:
8238678 - 财政年份:2009
- 资助金额:
$ 19.56万 - 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
- 批准号:
8036079 - 财政年份:2009
- 资助金额:
$ 19.56万 - 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
- 批准号:
7779486 - 财政年份:2009
- 资助金额:
$ 19.56万 - 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
- 批准号:
8435565 - 财政年份:2009
- 资助金额:
$ 19.56万 - 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
- 批准号:
8233407 - 财政年份:2009
- 资助金额:
$ 19.56万 - 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
- 批准号:
8574844 - 财政年份:2009
- 资助金额:
$ 19.56万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 19.56万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 19.56万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 19.56万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Standard Grant
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Operating Grants
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 19.56万 - 项目类别:
Fellowship